| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2022 | NOVOGLIA, INC. | 12 KAHLO CT | IRVINE | CA | 92617-5002 | ORANGE | USA | R43NS125730 | Enhancing the Engraftment of Microglia for the Treatment of Neurological Disease | 000 | 1 | NIH | 5/20/2024 | $0 |
| | 2024 | 2021 | NOVOGLIA, INC. | 12 KAHLO CT | IRVINE | CA | 92617-5002 | ORANGE | USA | R43NS124409 | Development of a stem cell platform for the treatment of neurodegenerativemicrogliopathies | 000 | 1 | NIH | 3/28/2024 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $399,859 ) |
| | 2022 | 2022 | NOVOGLIA, INC. | 12 KAHLO CT | IRVINE | CA | 92617-5002 | ORANGE | USA | R43NS125730 | Enhancing the Engraftment of Microglia for the Treatment of Neurological Disease | 001 | 1 | NIH | 8/26/2022 | $0 |
| | 2022 | 2022 | NOVOGLIA, INC. | 12 KAHLO CT | IRVINE | CA | 92617-5002 | ORANGE | USA | R43NS125730 | Enhancing the Engraftment of Microglia for the Treatment of Neurological Disease | 000 | 1 | NIH | 1/3/2022 | $399,859 |
| | 2022 | 2021 | NOVOGLIA, INC. | 12 KAHLO CT | IRVINE | CA | 92617-5002 | ORANGE | USA | R43NS124409 | Development of a stem cell platform for the treatment of neurodegenerativemicrogliopathies | 000 | 1 | NIH | 1/31/2022 | $0 |
| | 2022 | 2021 | NOVOGLIA, INC. | 12 KAHLO CT | IRVINE | CA | 92617-5002 | ORANGE | USA | R43NS124409 | Development of a stem cell platform for the treatment of neurodegenerativemicrogliopathies | 001 | 1 | NIH | 8/17/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $399,002 ) |
| | 2021 | 2021 | NOVOGLIA, INC. | 12 KAHLO CT | IRVINE | CA | 92617-5002 | ORANGE | USA | R43NS124409 | Development of a stem cell platform for the treatment of neurodegenerativemicrogliopathies | 000 | 1 | NIH | 9/24/2021 | $399,002 |
|
|
